Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Abstract Here we report on the humoral and cellular immune response in eight volunteers who autonomously chose to adhere to the Italian national COVID-19 vaccination campaign more than 3 months after receiving a single-administration GRAd-COV2 vaccine candidate in the context of the phase-1 clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiara Agrati, Stefania Capone, Concetta Castilletti, Eleonora Cimini, Giulia Matusali, Silvia Meschi, Eleonora Tartaglia, Roberto Camerini, Simone Lanini, Stefano Milleri, Stefano Colloca, Alessandra Vitelli, Antonella Folgori
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f46140408b3d4c32a683c443e605508a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f46140408b3d4c32a683c443e605508a
record_format	dspace
spelling	oai:doaj.org-article:f46140408b3d4c32a683c443e605508a2021-11-07T12:07:00ZStrong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV1910.1038/s41541-021-00394-52059-0105https://doaj.org/article/f46140408b3d4c32a683c443e605508a2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00394-5https://doaj.org/toc/2059-0105Abstract Here we report on the humoral and cellular immune response in eight volunteers who autonomously chose to adhere to the Italian national COVID-19 vaccination campaign more than 3 months after receiving a single-administration GRAd-COV2 vaccine candidate in the context of the phase-1 clinical trial. We observed a clear boost of both binding/neutralizing antibodies as well as T-cell responses upon receipt of the heterologous BNT162b2 or ChAdOx1-nCOV19 vaccines. These results, despite the limitation of the small sample size, support the concept that a single dose of an adenoviral vaccine may represent an ideal tool to effectively prime a balanced immune response, which can be boosted to high levels by a single dose of a different vaccine platform.Chiara AgratiStefania CaponeConcetta CastillettiEleonora CiminiGiulia MatusaliSilvia MeschiEleonora TartagliaRoberto CameriniSimone LaniniStefano MilleriStefano CollocaAlessandra VitelliAntonella FolgoriNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Chiara Agrati Stefania Capone Concetta Castilletti Eleonora Cimini Giulia Matusali Silvia Meschi Eleonora Tartaglia Roberto Camerini Simone Lanini Stefano Milleri Stefano Colloca Alessandra Vitelli Antonella Folgori Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
description	Abstract Here we report on the humoral and cellular immune response in eight volunteers who autonomously chose to adhere to the Italian national COVID-19 vaccination campaign more than 3 months after receiving a single-administration GRAd-COV2 vaccine candidate in the context of the phase-1 clinical trial. We observed a clear boost of both binding/neutralizing antibodies as well as T-cell responses upon receipt of the heterologous BNT162b2 or ChAdOx1-nCOV19 vaccines. These results, despite the limitation of the small sample size, support the concept that a single dose of an adenoviral vaccine may represent an ideal tool to effectively prime a balanced immune response, which can be boosted to high levels by a single dose of a different vaccine platform.
format	article
author	Chiara Agrati Stefania Capone Concetta Castilletti Eleonora Cimini Giulia Matusali Silvia Meschi Eleonora Tartaglia Roberto Camerini Simone Lanini Stefano Milleri Stefano Colloca Alessandra Vitelli Antonella Folgori
author_facet	Chiara Agrati Stefania Capone Concetta Castilletti Eleonora Cimini Giulia Matusali Silvia Meschi Eleonora Tartaglia Roberto Camerini Simone Lanini Stefano Milleri Stefano Colloca Alessandra Vitelli Antonella Folgori
author_sort	Chiara Agrati
title	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
title_short	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
title_full	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
title_fullStr	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
title_full_unstemmed	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
title_sort	strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine grad-cov2 and bnt162b2 or chadox1-ncov19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f46140408b3d4c32a683c443e605508a
work_keys_str_mv	AT chiaraagrati strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT stefaniacapone strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT concettacastilletti strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT eleonoracimini strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT giuliamatusali strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT silviameschi strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT eleonoratartaglia strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT robertocamerini strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT simonelanini strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT stefanomilleri strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT stefanocolloca strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT alessandravitelli strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19 AT antonellafolgori strongimmunogenicityofheterologousprimeboostimmunizationswiththeexperimentalvaccinegradcov2andbnt162b2orchadox1ncov19
_version_	1718443585470201856

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19

Ejemplares similares